Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Research Article

Tuberculosis Infection Under Anti-TNF Alpha Treatment

Author(s): Salma Athimni, Maroua Slouma*, Rim Dhahri , Imen Gharsallah, Leila Metoui and Bassem Louzir

Volume 17, Issue 3, 2022

Published on: 07 March, 2022

Page: [235 - 240] Pages: 6

DOI: 10.2174/1574886316666211109092354

Price: $65

Abstract

Background: Anti-tumor necrosis factor-α (TNF-α) is a life-changing treatment leading to quality-of-life improvement. Nonetheless, this treatment is associated with a high risk of infection, especially tuberculosis.

Objective: Our study aimed to determine the frequency of active tuberculosis in our patients with chronic rheumatic disease and treated with TNF-α.

Methods: We conducted a retrospective study including patients with Rheumatoid Arthritis and Spondylarthritis diagnosed according to ACR/EULAR 2009 criteria and ASAS 2010, respectively, and treated with biological agents for at least 6 months. We collected data regarding tuberculosis screening and the occurrence of active tuberculosis during follow-up.

Results: 82 patients were included (37 men and 45 women). The mean age was 42 ± 3.4 years. At inclusion, no patient had a medical history of tuberculosis. The diagnosis of latent tuberculosis infection was established in 17 patients (20.7%). Prophylactic treatment was prescribed in all these cases for three months. Two cases (2.4%) of active tuberculosis occurred under biologic (infliximab). It was two severe forms of tuberculosis. The first case had miliary tuberculosis associated with hepatic and peritoneal involvement. The second one had pleural tuberculosis. These two patients received anti-tuberculosis therapy, and the biological treatment was interrupted. Given the high disease activity, the anti-TNF-α was restarted after 3 and 4 months. There was no recurrence of tuberculosis after 7 years of follow-up.

Conclusion: The use of TNF-α blockers is associated with a risk of disseminated forms of tuberculosis. Tuberculosis screening, which is recommended before the biological onset, is also necessary under this treatment. Restarting the anti-TNF-α after appropriate treatment of tuberculosis seemed to be safe.

Keywords: Anti-tumor necrosis factor-α, tuberculosis, chronic rheumatic disease, Rheumatoid Arthritis, Spondylarthritis, prophylactic treatment.

Graphical Abstract
[1]
Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 2013; 5(Mar): 79-99.
[http://dx.doi.org/10.2147/DHPS.S28801] [PMID: 23569399]
[2]
Xie X, Li F, Chen J-W, Wang J. Risk of tuberculosis infection in anti-TNF-α biological therapy: From bench to bedside. J Microbiol Immunol Infect 2014; 47(4): 268-74.
[http://dx.doi.org/10.1016/j.jmii.2013.03.005] [PMID: 23727394]
[3]
Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003; 3(3): 148-55.
[http://dx.doi.org/10.1016/S1473-3099(03)00545-0] [PMID: 12614731]
[4]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[5]
Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68(6): 770-6.
[http://dx.doi.org/10.1136/ard.2009.108217] [PMID: 19297345]
[6]
Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis 2009; 68(6): 777-83.
[http://dx.doi.org/10.1136/ard.2009.108233] [PMID: 19297344]
[7]
Slouma M, Mahmoud I, Saidane O, Bouden S, Abdelmoula L. Latent tuberculosis infection screening prior to biological treatment in Tunisian patients. Therapie 2017; 72(5): 573-8.
[http://dx.doi.org/10.1016/j.therap.2017.02.002] [PMID: 28318613]
[8]
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345(15): 1098-104.
[http://dx.doi.org/10.1056/NEJMoa011110] [PMID: 11596589]
[9]
Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J 2010; 36(5): 1185-206.
[http://dx.doi.org/10.1183/09031936.00028510] [PMID: 20530046]
[10]
Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011; 364(15): 1441-8.
[http://dx.doi.org/10.1056/NEJMcp1005750] [PMID: 21488766]
[11]
Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology (Oxford) 2005; 44(10): 1205-6.
[http://dx.doi.org/10.1093/rheumatology/kei103] [PMID: 16172152]
[12]
Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004; 39(8): 1254-5.
[http://dx.doi.org/10.1086/424455] [PMID: 15486857]
[13]
Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2(11): 602-10.
[http://dx.doi.org/10.1038/ncprheum0336] [PMID: 17075599]
[14]
Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69(3): 522-8.
[http://dx.doi.org/10.1136/ard.2009.118935] [PMID: 19854715]
[15]
Global Tuberculosis Programme. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. Available from: http://www.ncbi.nlm.nih.gov/books/NB K531235/
[16]
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection.N Engl J Med. 2015; 372: pp. (22)2127-35.
[17]
Hur Y-G, Kang YA, Jang S-H, et al. Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects. J Infect 2015; 70(4): 346-55.
[http://dx.doi.org/10.1016/j.jinf.2014.10.019] [PMID: 25452040]
[18]
Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-γ test. Respir Res 2006; 7(1): 56.http://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-7-56
[http://dx.doi.org/10.1186/1465-9921-7-56] [PMID: 16579856]
[19]
Smith R, Cattamanchi A, Steingart KR, et al. Interferon-γ release assays for diagnosis of latent tuberculosis infection: Evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011; 23(4): 377-84.
[http://dx.doi.org/10.1097/BOR.0b013e3283474d62] [PMID: 21519268]
[20]
Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 2018; 16(6): 501-12.
[http://dx.doi.org/10.1080/14787210.2018.1483238] [PMID: 29848120]
[21]
Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis 2017; 20(10): 1313-25.
[http://dx.doi.org/10.1111/1756-185X.13129] [PMID: 28730751]
[22]
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64(5): 625-39.
[http://dx.doi.org/10.1002/acr.21641] [PMID: 22473917]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy